Marker Therapeutics (MRKR) Common Equity (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Common Equity of $13.8 million for Q1 2026, down 4.8% year-over-year from $14.5 million in Q1 2025, and down 17.87% quarter-over-quarter from $16.8 million in Q4 2025.
Marker Therapeutics (MRKR) Common Equity (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Common Equity for 17 consecutive years, with $13.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 4.8% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $13.8 million (down 4.8% YoY), while the FY2025 annual figure was $16.8 million, down 9.49% from the prior year.
- Common Equity slipped to $13.8 million in Q1 2026 per MRKR's latest filing, from $16.8 million in the prior quarter.
- Across five years, Common Equity topped out at $35.7 million in Q1 2022 and bottomed at $7.4 million in Q3 2024.
- Historically, Common Equity has averaged $17.2 million across 5 years, with a median of $16.7 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity sank 56.77% — and 2025, when it soared 146.84%.
- Marker Therapeutics' Common Equity stood at $19.6 million in 2022, then retreated by 28.31% to $14.1 million in 2023, then soared by 32.06% to $18.6 million in 2024, then fell by 9.49% to $16.8 million in 2025, then slipped by 17.87% to $13.8 million in 2026.
- Business Quant data shows MRKR's Common Equity at $13.8 million in Q1 2026, $16.8 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 12.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.80 Mn |
| Dec 31, 2025 | 16.80 Mn |
| Sep 30, 2025 | 18.39 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Mar 31, 2025 | 14.49 Mn |
| Dec 31, 2024 | 18.56 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 11.79 Mn |
| Dec 31, 2023 | 14.05 Mn |
| Sep 30, 2023 | 16.71 Mn |
| Jun 30, 2023 | 19.03 Mn |
| Mar 31, 2023 | 15.91 Mn |
| Dec 31, 2022 | 19.60 Mn |
| Sep 30, 2022 | 22.60 Mn |
| Jun 30, 2022 | 28.03 Mn |
| Mar 31, 2022 | 35.71 Mn |
| Dec 31, 2021 | 43.99 Mn |
| Sep 30, 2021 | 52.28 Mn |
| Jun 30, 2021 | 63.24 Mn |